Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

Completed · Not applicable · Has a placebo group

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to examine the role of a well-known and well-tolerated antibiotic, doxycycline, in the treatment of cystic fibrosis patients who are hospitalized. This antibiotic does not effectively treat the bacteria in airways of cystic fibrosis patients, but may reduce the activity of inflammatory molecules in the disease.

Key facts

Study ID

NCT01112059

Run by

University of Alabama at Birmingham

People needed

40

Starts

2008-11-01

Expected to finish

2012-11-01

Last updated by the study team

2017-03-06

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cystic Fibrosis
• Hospitalization for Pulmonary exacerbation

You may not qualify if…

• Significant GI illness
• Participation in another Investigational Protocol
• Allergies to Doxycycline
• Sputum Culture only positive for Staphylococcus aureus,
• Pregnant or Nursing
• Unwilling to use effective birth control
• Elevated LFT's greater than 3x the upper limit of normal
• Creatinine greater than 1.5x the upper limit of normal
• Lung transplantation
• Substance abuse within 30 days of screening

Where it is running

• University of alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.